KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Financing Activities (2017 - 2025)

Aquestive Therapeutics has reported Cash from Financing Activities over the past 9 years, most recently at $660000.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $660000.0 for Q4 2025, up 320.38% from a year ago — trailing twelve months through Dec 2025 was $102.6 million (up 22.76% YoY), and the annual figure for FY2025 was $102.6 million, up 22.76%.
  • Cash from Financing Activities for Q4 2025 was $660000.0 at Aquestive Therapeutics, down from $81.4 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for AQST hit a ceiling of $81.7 million in Q1 2024 and a floor of -$9.2 million in Q1 2023.
  • Median Cash from Financing Activities over the past 5 years was $4.1 million (2023), compared with a mean of $11.6 million.
  • Biggest five-year swings in Cash from Financing Activities: crashed 809.17% in 2023 and later surged 478988.24% in 2025.
  • Aquestive Therapeutics' Cash from Financing Activities stood at $5.5 million in 2021, then plummeted by 95.71% to $234000.0 in 2022, then soared by 1572.22% to $3.9 million in 2023, then crashed by 95.99% to $157000.0 in 2024, then soared by 320.38% to $660000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $660000.0 (Q4 2025), $81.4 million (Q3 2025), and -$100000.0 (Q2 2025) per Business Quant data.